However, BRAF inhibitor monotherapy showed a low response rate in BRAF-MT mCRC [6,7,8] because rebound feedback with increased signaling through the epidermal growth factor receptor (EGFR) pathway after BRAF inhibition occurs in colon cancer [9,10]. The gene discussed is EGFR; the disease is colonic neoplasm.